Adult Dosing
Attention deficit hyperactivity disorder
- Initial Dose: 30 mg PO daily taken in the morning
- If needed increase by 10-20 mg/day qwk
- Max: 70 mg/day
Note: Individualize dosage according to the therapeutic needs and response of the patient
Pediatric Dosing
Attention deficit hyperactivity disorder
- Age
6 yrs : Initial Dose: 30 mg PO daily taken in the morning - If needed increase by 10-20 mg/day qwk
- Max: 70 mg/day
Note: Individualize dosage according to the therapeutic needs and response of the patient
[Outline]
See Supplemental Patient Information
- Sudden death has occurred in CNS stimulant treated children and adolescents with structural cardiac abnormalities or other serious heart problems. Avoid use in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems
- Sudden death, stroke, and myocardial infarctions have occurred in adults taking stimulant drugs at usual doses for ADHD. Avoid use in adults having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Therapy may increase blood pressure on average about 2-4 mm Hg and heart rate on average about 3-6 bpm. Monitor patients for greater changes in heart rate and blood pressure
- Consider undertaking assessment for a familial history of sudden death or ventricular arrhythmia and perform a physical examination to assess the presence of cardiac disease and if furthur cardiac evaluations may be necessary if findings suggest such disease
- Exacerbation of symptoms of behavior disturbance and thought disorder has occurred in patients with a pre-existing psychotic disorder. Adequate care is necessary in using stimulants to treat ADHD in patients with comorbid bipolar disorder as induction of a mixed/manic episode has occurred. Undertake detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression in such patients prior to initiation of treatment
- Consider a possible causal role of the stimulant, and discontinue therapy on emergence of new psychotic or manic symptoms in children and adolescents
- Monitor patients treated for ADHD for the appearance of, or worsening of, aggressive behavior or hostility
- Therapy is associated with lowering the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. Discontinue therapy with presence of seizures
- Difficulties with accommodation and blurring of vision have occurred
- Clinically evaluate patients for tics and Tourette’s syndrome
- Monitor growth (weight and height) in pediatric patients during therapy and interrupt therapy in patients who are not growing or gaining weight as expected
- Prescribe the least amount of amphetamine or dispense at one time in order to minimize the possibility of overdosage
- Therapy is associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms usually improve after reduction in dose or discontinuation of therapy
Cautions: Use cautiously in
- History of cardiovascular disease
- Mild hypertension
- Psychosis
- Bipolar disorder
- Tourette syndrome or tics
- Risk of seizure
- History of seizure
- Patients using concomitant sympathomimetic drugs
Supplemental Patient Information
- Inform patients, their families, and their caregivers about the potential benefits and risks associated with this drug and counsel them on its appropriate use
- Advise to store the product in a safe place to prevent misuse and/or abuse
- Instruct patients to report to their physician about any numbness, pain, skin color change, or sensitivity to temperature in fingers or toes
Pregnancy Category:C
Breastfeeding: This drug is a prodrug of dextroamphetamine. In prescribed dosages for medical indications, some evidence indicates that dextroamphetamine does not affect nursing infants adversely. The effect of dextroamphetamine in milk on the neurological development of the infant has not been well established. Larger dosages of dextroamphetamine interfere with milk production, especially in women whose lactation is not well established. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 4 February 2011). Manufacturer advises mothers taking amphetamines to refrain from nursing.
Pricing data from www.DrugStore.com in U.S.A.
- Vyvanse 20 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $125.99
30 mg = $177.98 - Vyvanse 70 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $117.98
30 mg = $171.45 - Vyvanse 50 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $118.57
30 mg = $171.45 - Vyvanse 40 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $113.99
30 mg = $170.97 - Vyvanse 60 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $117.7
30 mg = $176.56 - Vyvanse 30 MG CAPS [Bottle] (SHIRE US INC.)
20 mg = $126.99
30 mg = $189.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
